Y-Intercept (HK)’s Denali Therapeutics DNLI Stock Holding History

Y-Intercept (HK)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-78,007	Closed	-$1.5M	–	1812
2026 Q1	$1.5M	Sell	78,007 -15,580	-17%	-$310K	0.03%	854
2025 Q4	$1.55M	Buy	+93,587	New	+$1.58M	0.03%	750
2025 Q2	–	Sell	-54,813	Closed	-$745K	–	1710
2025 Q1	$745K	Buy	54,813 +18,807	+52%	+$360K	0.05%	526
2024 Q4	$734K	Buy	36,006 +22,183	+160%	+$568K	0.05%	558
2024 Q3	$403K	Sell	13,823 -25,369	-65%	-$629K	0.02%	881
2024 Q2	$910K	Buy	+39,192	New	+$752K	0.05%	534
2023 Q4	–	Sell	-26,618	Closed	-$549K	–	1322
2023 Q3	$549K	Buy	+26,618	New	+$675K	0.05%	532
2021 Q2	–	Sell	-4,886	Closed	-$265K	–	682
2021 Q1	$265K	Buy	+4,886	New	+$327K	0.07%	457

Other funds holding DNLI

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

SOAM

SBI Okasan Asset Management Tokyo, Japan $3.04B AUM

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

BCG

Breakwater Capital Group Paramus, New Jersey $833M AUM 22.71% 1-Year Est. Return

CIM

Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

Y-Intercept (HK)'s DNLI Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 78,007 shares — an estimated $1.5M sold.

Y-Intercept (HK) first reported a position in DNLI in Q1 2021 and held it in 8 quarters. The position peaked at $1.55M in Q4 2025. 41 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Y-Intercept (HK) reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 78,007 Denali Therapeutics shares in Q2 2026, an estimated $1.5M.
Y-Intercept (HK) first reported a position in Denali Therapeutics in Q1 2021 and held it in 8 quarters.
Y-Intercept (HK)'s Denali Therapeutics position peaked at $1.55M in Q4 2025.
41 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.